A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.
Study Details
Study Description
Brief Summary
To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Detailed Description
Cohorts of 16 patients receive 1 of 2 doses of Ro 31-8959 for 20 weeks. Administration of the higher dose will proceed only after 2-week safety data for the first eight patients on the lower dose has been reviewed.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria
Patients must have:
-
Documented HIV infection.
-
CD4 count 200 - 500 cells/mm3.
-
No evidence of viral resistance.
-
HIV RNA quantifiable by PCR.
-
Negativity for HBsAg, HBeAg, and anti-HBc.
NOTE:
- Fifty percent of patients must have measurable p24 antigen levels (> 31 pg/ml).
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
-
Active opportunistic infection requiring immediate treatment, such as tuberculosis, cytomegalovirus, cerebral toxoplasmosis, and Pneumocystis carinii pneumonia.
-
Unable to maintain adequate oral intake.
-
Clinically significant vomiting and/or diarrhea.
-
Malignancy, visceral Kaposi's sarcoma, or lymphoma that will require systemic chemotherapy within the next 12 months.
-
Unable to comply with protocol requirements, in the judgment of the investigator.
-
Any grade 3 or worse laboratory or clinical abnormality.
Concurrent Medication:
Excluded:
-
Antineoplastic agents.
-
Concomitant or maintenance treatment with excluded experimental drugs and drugs with known nephrotoxic or hepatotoxic potential.
Concurrent Treatment:
Excluded:
- Radiation therapy other than local skin radiation therapy.
Patients with the following prior conditions are excluded:
-
Unexplained temperature >= 38.5 C (101.5 F) persisting for 14 days or more within a 30-day period.
-
Unexplained, chronic diarrhea persisting for 14 days or more within a 30-day period.
Prior Medication:
Excluded:
-
Prior treatment with an HIV proteinase inhibitor.
-
AZT within 30 days prior to study entry OR lasting more than 1 year.
-
Other antiretroviral therapy (besides AZT) within 30 days prior to study entry OR lasting more than 14 days.
-
Acute therapy for an opportunistic infection within 14 days prior to study entry.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Stanford Univ School of Medicine | Stanford | California | United States | 943055107 |
Sponsors and Collaborators
- Stanford University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- 212A
- EV 14757